Astex Pharmaceuticals, Inc. (ASTX)

Oncology Corporate Profile

Stock Performance

8.4950
0.0000

3 Month Stock History Chart

HQ Location

4140 Dublin Blvd. Suite 200
Dublin, CA 94568

Company Description

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen and receives significant royalties on global sales.

Website: http://astx.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
guadecitabine / SGI-110DNMT inhibitorAcute Myelogenous Leukemia (AML)III
ASTX727DNMT inhibitorVarious cancer typesII
guadecitabine / SGI-110DNMT inhibitorVarious cancer typesII
onalespib / AT13387Hsp90 inhibitorVarious cancer typesII
erdafitinib / JNJ42756493FGFR inhibitorVarious cancer typesIIJanssen
AZD5363PKB/Akt inhibitorVarious cancer typesIIAstraZeneca
ASTX660Dual IAP AntagonistLymphomaI
ASTX660Dual IAP AntagonistVarious cancer typesI
AT7519CDK inhibitorVarious cancer typesI
ribociclib / LEE011CDK4/6 inhibitor1st line Breast cancerApprovedNovartis

View additional information on product candidates here »

Source: http://astx.com/

Recent News Headlines

Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) With Atezolizumab in the Treatment of Acute Myeloid Leukemia

4/20/2016 05:12 pm

(Astex) Apr 19, 2016 - Astex Pharmaceuticals, Inc. announced today that it has entered into a clinical collaboration with Genentech to evaluate the potential for combining Astex’s next generation hypomethylating agent, guadecitabine (SGI-110), with Genentech’s investigational anti-PD-L1 monoclonal antibody, atezolizumab, in the treatment of acute myeloid leukemia (AML).

Astex Pharmaceuticals Announces Orphan Drug Designation for Guadecitabine (SGI-110) in the Treatment of Acute Myeloid Leukemia

10/7/2015 04:49 pm

(Yahoo! Finance) Oct 6, 2015 - Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced today that its novel hypomethylating agent, guadecitabine (SGI-110), has been granted an orphan drug designation by the US FDA.

Breast Cancer Vaccine Shows Promise in Slowing Progress

12/1/2014 11:03 am

(Time.com) Dec 1, 2014 - An initial safety trial of a breast cancer vaccine has proven safe, with preliminary results suggesting the vaccine will slow cancer progression.

Astex Pharmaceuticals Presents Final Results of Phase 2 Study of SGI-110 in Treatment Naïve Elderly Acute Myeloid Leukemia at the European Hematology Association Meeting

6/16/2014 04:46 pm

(MarketWatch) June 16, 2014 - Astex Pharmaceuticals presented the final results of a Phase 2 study of SGI-110, a novel hypomethylating agent in elderly Acute Myeloid Leukemia (AML) in an oral session on June 14 at the European Hematology Association meeting held in Milan, Italy (June 12-15).

Astex Pharmaceuticals Presents Final Results of Phase 2 Study of SGI-110 in Treatment Naïve Elderly Acute Myeloid Leukemia at the European Hematology Association Meeting

6/16/2014 06:04 am

(MarketWatch) June 16, 2014 - Astex Pharmaceuticals presented the final results of a Phase 2 study of SGI-110, a novel hypomethylating agent in elderly Acute Myeloid Leukemia (AML) in an oral session on June 14 at the European Hematology Association meeting held in Milan, Italy (June 12-15).

Astex Joins UK Alliance to Trial Potential New Cancer Drugs

5/14/2014 04:29 pm

(Drug Discovery & Development) May 14, 2014 - Cancer Research UK’s Drug Development Office (DDO) announced that Astex Pharmaceuticals will join its Experimental Cancer Medicine Center (ECMC) Combinations Alliance with an aim to develop new cancer treatments.

Astex Joins UK Alliance to Trial Potential New Cancer Drugs

5/14/2014 06:02 am

(Drug Discovery & Development) May 14, 2014 - Cancer Research UK’s Drug Development Office (DDO) announced that Astex Pharmaceuticals will join its Experimental Cancer Medicine Center (ECMC) Combinations Alliance with an aim to develop new cancer treatments.

Astex Earns Milestone Payment on Initiation of Phase 3 Study

3/5/2014 05:53 pm

(Yahoo! Finance) Mar 4, 2014 - Astex Pharmaceuticals announced that it has received a milestone payment triggered by the commencement, by Novartis, of a Phase 3 study of LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6.

Astex Earns Milestone Payment on Initiation of Phase 3 Study

3/5/2014 11:05 am

(Yahoo! Finance) Mar 4, 2014 - Astex Pharmaceuticals announced that it has received a milestone payment triggered by the commencement, by Novartis, of a Phase 3 study of LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6.

Astex Pharma Shareholder Opposes $886 Mln Bid by Otsuka

10/3/2013 04:57 pm

(Reuters) Oct 2, 2013 - Otsuka Holdings Co's $886 million bid for Astex Pharmaceuticals Inc has run into opposition from an activist shareholder who says the deal significantly undervalues the U.S. biotech firm - a charge that Astex has denied.

Astex Pharma Shareholder Opposes $886 Mln Bid by Otsuka

10/3/2013 11:05 am

(Reuters) Oct 2, 2013 - Otsuka Holdings Co's $886 million bid for Astex Pharmaceuticals Inc has run into opposition from an activist shareholder who says the deal significantly undervalues the U.S. biotech firm - a charge that Astex has denied.

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 AML Data at the European Cancer Congress

9/30/2013 02:18 pm

(Reuters) Sep 30, 2013 - Astex Pharmaceuticals, Inc. today announced that detailed clinical responses and biomarkers data of relapsed/refractory AML (r/r AML) patients treated in the Phase 1 part of the SGI-110-01 study were presented at the European Cancer Congress (ECC: ECCO-ESMO-ESTRO) in Amsterdam, Netherlands.

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 AML Data at the European Cancer Congress

9/30/2013 09:01 am

(Reuters) Sep 30, 2013 - Astex Pharmaceuticals, Inc. today announced that detailed clinical responses and biomarkers data of relapsed/refractory AML (r/r AML) patients treated in the Phase 1 part of the SGI-110-01 study were presented at the European Cancer Congress (ECC: ECCO-ESMO-ESTRO) in Amsterdam, Netherlands.

Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals for $8.50 Per Share in Cash

9/5/2013 05:47 pm

(Astex) Sep 5, 2013 - Otsuka Pharmaceutical Co., Ltd. and Astex Pharmaceuticals, Inc., announced today that their respective Boards of Directors have unanimously approved a transaction under which Otsuka will acquire all of the outstanding shares of Astex for $8.50 per share in cash representing a 48% premium to the average closing stock price for the prior 30 day period.

Otsuka Pharma to Buy Cancer Drug Developer Astex for $886 Million — Really

9/5/2013 05:20 pm

(San Francisco Business Times) Sep 5, 2013 - Japan’s Otsuka Pharmaceutical Co. Ltd., the maker of the depression treatment Ablify, will buy cancer drug developer Astex Pharmaceuticals Inc. in an $886 million all-cash deal, the companies said early Thursday.

Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals for $8.50 Per Share in Cash

9/5/2013 12:04 pm

(Astex) Sep 5, 2013 - Otsuka Pharmaceutical Co., Ltd. and Astex Pharmaceuticals, Inc., announced today that their respective Boards of Directors have unanimously approved a transaction under which Otsuka will acquire all of the outstanding shares of Astex for $8.50 per share in cash representing a 48% premium to the average closing stock price for the prior 30 day period.

Otsuka Pharma to Buy Cancer Drug Developer Astex for $886 Million — Really

9/5/2013 12:02 pm

(San Francisco Business Times) Sep 5, 2013 - Japan’s Otsuka Pharmaceutical Co. Ltd., the maker of the depression treatment Ablify, will buy cancer drug developer Astex Pharmaceuticals Inc. in an $886 million all-cash deal, the companies said early Thursday.

Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals for $8.50 Per Share in Cash

9/5/2013 06:00 am

(Astex) Sep 5, 2013 - Otsuka Pharmaceutical Co., Ltd. and Astex Pharmaceuticals, Inc., announced today that their respective Boards of Directors have unanimously approved a transaction under which Otsuka will acquire all of the outstanding shares of Astex for $8.50 per share in cash representing a 48% premium to the average closing stock price for the prior 30 day period.

Biotech Stock Mailbag: Astex Pharma, My Essential Twitter Follows

8/30/2013 04:04 pm

(The Street) Aug 30, 2013 - Astex shares rose 25% Wednesday (and remained flat Thursday) following the release of interim results from a phase II study of SGI-110, a next-generation DNA-hypomethylating agent under development for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) -- two forms of blood cancer that affect myeloid cells.

Biotech Stock Mailbag: Astex Pharma, My Essential Twitter Follows

8/30/2013 11:00 am

(The Street) Aug 30, 2013 - Astex shares rose 25% Wednesday (and remained flat Thursday) following the release of interim results from a phase II study of SGI-110, a next-generation DNA-hypomethylating agent under development for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) -- two forms of blood cancer that affect myeloid cells.

Astex Pharmaceuticals Announces Topline Results of SGI-110 AML Phase 2 Study

8/28/2013 03:49 pm

(Yahoo! Finance) Aug 28, 2013 - SGI-110 phase 2 shows clear activity in patients with Acute Myeloid Leukemia (AML).

Astex Pharmaceuticals Announces Topline Results of SGI-110 AML Phase 2 Study

8/28/2013 10:04 am

(Yahoo! Finance) Aug 28, 2013 - SGI-110 phase 2 shows clear activity in patients with Acute Myeloid Leukemia (AML).

Scientists ID New Kidney Cancer Subtypes, Clearing Way for Personalized Treatment

4/17/2013 11:05 am

(UCLA News) Apr 16, 2013 - Researchers with UCLA's Institute of Urologic Oncology and department of urology have classified kidney cancer into several unique subtypes, a breakthrough that will help physicians tailor treatment to individual kidney cancer patients, moving cancer care one step closer to personalized medicine.

Astex Pharmaceuticals Provides SGI-110 Update

4/10/2013 04:58 pm

(TheStreet) Apr 10, 2013 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that SGI-110 was featured in an oral presentation on Tuesday, April 9 at the American Association of Cancer Research (AACR) in Washington, DC.

Astex Pharmaceuticals Provides SGI-110 Update

4/10/2013 11:05 am

(TheStreet) Apr 10, 2013 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that SGI-110 was featured in an oral presentation on Tuesday, April 9 at the American Association of Cancer Research (AACR) in Washington, DC.

Central Venous Catheter Care for the Patient With Cancer: American Society of Clinical Oncology Clinical Practice Guideline

3/5/2013 11:04 am

(ASCO) Mar 4, 2013 - Purpose: To develop an evidence-based guideline on central venous catheter (CVC) care for patients with cancer that addresses catheter type, insertion site, and placement as well as prophylaxis and management of both catheter-related infection and thrombosis.

Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Advanced Hepatocellular Carcinoma (HCC) Patients

1/2/2013 07:16 pm

(NASDAQ) Jan 2, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated a Phase 2, open-label, single-arm, non-randomized clinical trial, evaluating SGI-110 in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with Nexavar (sorafenib).

Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Advanced Hepatocellular Carcinoma (HCC) Patients

1/2/2013 01:01 pm

(NASDAQ) Jan 2, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated a Phase 2, open-label, single-arm, non-randomized clinical trial, evaluating SGI-110 in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with Nexavar (sorafenib).

Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH

12/10/2012 11:20 pm

(Yahoo! Finance) Dec 10, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced encouraging Phase I clinical results during a presentation at the American Society of Hematology (ASH) of SGI-110, a novel second generation hypomethylation agent.

Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH

12/10/2012 05:02 pm

(Yahoo! Finance) Dec 10, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced encouraging Phase I clinical results during a presentation at the American Society of Hematology (ASH) of SGI-110, a novel second generation hypomethylation agent.

U-M Study Finds Overuse of Diagnostic Imaging Prevalent in Patients with Early Stage Breast Cancer

12/4/2012 11:04 am

(U-M Health System) Dec 4, 2012 - Limiting advanced imaging tests such as CT scans for patients with early stage breast cancer can improve the quality and reduce the cost of care, yet a new University of Michigan Comprehensive Cancer Center study shows many patients still receive such tests despite being at low risk for recurrence.

Strategic Drug Discovery Alliance Signed by CRT, Astex Pharmaceuticals and Newcastle University

10/29/2012 04:37 pm

(Cancer Research UK) Oct 29, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and Newcastle University have signed a major five-year strategic drug discovery alliance.

Strategic Drug Discovery Alliance Signed by CRT, Astex Pharmaceuticals and Newcastle University

10/29/2012 11:03 am

(Cancer Research UK) Oct 29, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and Newcastle University have signed a major five-year strategic drug discovery alliance.

Astex Pharmaceuticals Announces Initiation of AT13387 Phase 2 Study in Non-Small Cell Lung Cancer

10/24/2012 04:33 pm

(Yahoo! Finance) Oct 24, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated an open label, randomized, controlled, multi-center, Phase 2 clinical trial, evaluating HSP90 inhibitor AT13387 in anaplastic lymphoma kinase positive (ALK +) non-small cell lung cancer patients or other potentially crizotinib-sensitive NSCLC patients who have been receiving crizotinib.

Astex Pharmaceuticals Announces Initiation of AT13387 Phase 2 Study in Non-Small Cell Lung Cancer

10/24/2012 11:03 am

(Yahoo! Finance) Oct 24, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated an open label, randomized, controlled, multi-center, Phase 2 clinical trial, evaluating HSP90 inhibitor AT13387 in anaplastic lymphoma kinase positive (ALK +) non-small cell lung cancer patients or other potentially crizotinib-sensitive NSCLC patients who have been receiving crizotinib.

Astex Pharmaceuticals Earns $5 Million for First Commercial Sale of DACOGEN(R) in the European Union

10/9/2012 04:56 pm

(NASDAQ) Oct 9, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that a $5 million dollar milestone was earned from Eisai Inc., for the first commercial sale of DACOGEN® in the European Union.

Astex Pharmaceuticals Earns $5 Million for First Commercial Sale of DACOGEN(R) in the European Union

10/9/2012 11:05 am

(NASDAQ) Oct 9, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that a $5 million dollar milestone was earned from Eisai Inc., for the first commercial sale of DACOGEN® in the European Union.

Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Platinum-Resistant Recurrent Ovarian Cancer Patients

10/2/2012 06:32 pm

(NASDAQ) Oct 2, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated a Phase 2, open label, randomized, multi-center, controlled clinical trial, evaluating SGI-110 in combination with carboplatin in platinum-resistant recurrent ovarian cancer patients.

Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Platinum-Resistant Recurrent Ovarian Cancer Patients

10/2/2012 01:03 pm

(NASDAQ) Oct 2, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated a Phase 2, open label, randomized, multi-center, controlled clinical trial, evaluating SGI-110 in combination with carboplatin in platinum-resistant recurrent ovarian cancer patients.

Astex Says EU OKs Marketing for its Leukemia Drug

9/28/2012 02:57 pm

(Marketwatch/Dow Jones Newswires) Sept 28, 2012 - Astex Pharmaceuticals Inc. said the European Commission has approved marketing authorization for Dacogen to treat a type of leukemia.

Astex Says EU OKs Marketing for its Leukemia Drug

9/28/2012 09:05 am

(Marketwatch/Dow Jones Newswires) Sept 28, 2012 - Astex Pharmaceuticals Inc. said the European Commission has approved marketing authorization for Dacogen to treat a type of leukemia.

Astex Pharma Ends Development of Lung Cancer Drug

9/21/2012 01:26 pm

(Reuters) Sept 21, 2012 - Astex Pharmaceuticals Inc said it would discontinue the development of its experimental small-cell lung cancer drug amuvatinib as the drug failed to meet the main goal of a mid-stage study.

Astex Pharma Ends Development of Lung Cancer Drug

9/21/2012 08:02 am

(Reuters) Sept 21, 2012 - Astex Pharmaceuticals Inc said it would discontinue the development of its experimental small-cell lung cancer drug amuvatinib as the drug failed to meet the main goal of a mid-stage study.

Astex Pharmaceuticals Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in Prostate Cancer Patients

9/10/2012 04:21 pm

(Yahoo! Finance) Sept 10, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated a clinical trial with HSP90 inhibitor AT13387 in prostate cancer patients.

Astex Pharmaceuticals Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in Prostate Cancer Patients

9/10/2012 11:02 am

(Yahoo! Finance) Sept 10, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated a clinical trial with HSP90 inhibitor AT13387 in prostate cancer patients.

Astex Pharmaceuticals, Cancer Research Technology and The Institute of Cancer Research Announce Epigenetic Drug Discovery Collaboration

9/6/2012 05:21 pm

(TheStreet) Sept 6, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.

Astex Pharmaceuticals, Cancer Research Technology and The Institute of Cancer Research Announce Epigenetic Drug Discovery Collaboration

9/6/2012 12:02 pm

(TheStreet) Sept 6, 2012 - Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.